Background: Mosapride, a gastroprokinetic agent that acts as a selective 5HT4 agonist, is used for the treatment of gastritis, gastro-oesophageal reflux disease, functional dyspepsia and irritable bowel syndrome. Non-steroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling. Peptic ulcer is a major side effect of NSAIDs. In this study we tested the effect of oral administration of mosapride 0.25, 0.5, 0.75, 1.25, 2.5 and 5mg/kg on gastric mucosa and on NSAIDs induced gastric ulcers in rats. Methods: Acute gastric ulcers were induced in rats by the oral administration of indomethacin. Results: Mosapride had no effect on gastric mucosa but increased the prostaglandin E2 (PGE2) level. Pretreatment with mosapride at 0.25 and 0.5 mg/kg prevented the mucosal damage induced by indomethacin. The higher doses, from 0.75 up to 5mg/kg, had no effect on indomethacin-induced gastric ulcer. Conclusion: Mosapride had no effect on gastric mucosa but increased PGE2 and demonstrated antiulcer effect in small doses only. This effect could be partially mediated through increased prostaglandin E2.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.